Free Trial

HC Wainwright Reaffirms "Buy" Rating for Alphatec (NASDAQ:ATEC)

Alphatec logo with Medical background

Alphatec (NASDAQ:ATEC - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the medical technology company's stock. HC Wainwright's price target indicates a potential upside of 79.86% from the company's previous close.

Other analysts have also issued reports about the company. Barclays raised their price target on Alphatec from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 19th. Needham & Company LLC lifted their target price on Alphatec from $13.00 to $16.00 and gave the company a "buy" rating in a report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and a consensus price target of $17.44.

Check Out Our Latest Stock Analysis on ATEC

Alphatec Price Performance

Alphatec stock traded up $0.24 during midday trading on Tuesday, reaching $11.12. 2,321,717 shares of the company were exchanged, compared to its average volume of 2,052,927. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -8.69 and a beta of 1.41. Alphatec has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm's 50-day simple moving average is $9.49 and its 200-day simple moving average is $8.00.

Insider Activity

In related news, EVP David Sponsel sold 58,283 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now owns 502,311 shares of the company's stock, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Several hedge funds have recently bought and sold shares of ATEC. XTX Topco Ltd bought a new stake in Alphatec in the third quarter worth $69,000. Net Worth Advisory Group bought a new position in shares of Alphatec in the third quarter worth about $76,000. Tempus Wealth Planning LLC acquired a new position in shares of Alphatec during the 3rd quarter worth about $107,000. Van ECK Associates Corp boosted its stake in Alphatec by 57.0% during the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock valued at $99,000 after purchasing an additional 6,998 shares during the period. Finally, Atria Investments Inc grew its stake in shares of Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company's stock worth $109,000 after acquiring an additional 1,460 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Further Reading

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Should You Invest $1,000 in Alphatec Right Now?

Before you consider Alphatec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.

While Alphatec currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Explosive Growth: Buy Now or Wait for a Dip?
5 Stocks to BUY NOW in February 2025
How To Invest in Crypto as A Complete BEGINNER in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines